Recurrent Spliceosome Mutations in Cancer: Mechanisms and Consequences of Aberrant Splice Site Selection

Area of Science:

• Molecular Biology
• Cancer Biology
• Genetics

Background:

• Splicing alterations and aberrant isoform variants are hallmarks of cancer, supporting tumor cell proliferation and dissemination.
• The spliceosome, a complex machinery, catalyzes RNA splicing, involving intron removal and exon ligation.
• Recurrent hotspot mutations in key spliceosome components (U1 snRNA, SF3B1, U2AF1) are increasingly identified across various cancer types.

Purpose of the Study:

• To review the molecular mechanisms by which mutations in spliceosome components influence cancer development.
• To elucidate how these mutations affect splice site selection and contribute to oncogenesis.

Main Methods:

• Literature review of studies investigating spliceosome mutations in cancer.
• Analysis of molecular data linking spliceosome component mutations to altered splicing patterns.
• Focus on the functional impact of U1 snRNA, SF3B1, and U2AF1 mutations on splice site recognition.

Main Results:

• Mutations in U1 snRNA, SF3B1, and U2AF1, despite being detrimental to normal cellular function, are selected for in cancer.
• These mutations critically impair accurate splice site selection, affecting both 5′ and 3′ splice sites.
• The aberrant splicing patterns resulting from these mutations contribute to the development and progression of specific cancers.

Conclusions:

• Mutations in spliceosome components represent a significant mechanism driving cancer development.
• Understanding these mutations' impact on splicing is crucial for developing targeted cancer therapies.
• Further research into spliceosome function in cancer holds promise for novel therapeutic strategies.